Literature DB >> 16705732

Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.

G Grana1.   

Abstract

Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive early breast cancer. However, the side-effects associated with tamoxifen therapy have prompted a search for safer and potentially more effective endocrine agents. Results from randomized trials of the third-generation aromatase inhibitors, anastrozole, letrozole and exemestane, demonstrating improved efficacy compared with tamoxifen and favorable tolerability profiles, are discussed in this review. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16705732     DOI： 10.1002/jso.20564

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  5 in total

Review 1.  Aromatase inhibitors: past, present and future in breast cancer therapy.

Authors:  Udayan Dutta; Kartikeya Pant
Journal:  Med Oncol       Date:  2007-11-01       Impact factor: 3.064

2.  Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics.

Authors:  Dongxiao Sun; Gang Chen; Ryan W Dellinger; Arun K Sharma; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

3.  [F]fluoro-2-deoxy-d-glucose incorporation by mcf-7 breast tumour cells in vitro is modulated by treatment with tamoxifen, Doxorubicin, and docetaxel: relationship to chemotherapy-induced changes in ATP content, hexokinase activity, and glucose transport.

Authors:  R I Sharma; A E Welch; L Schweiger; S Craib; T A D Smith
Journal:  Int J Mol Imaging       Date:  2010-10-26

4.  Role of the UGT2B17 deletion in exemestane pharmacogenetics.

Authors:  S Luo; G Chen; C Truica; C C Baird; K Leitzel; P Lazarus
Journal:  Pharmacogenomics J       Date:  2017-05-23       Impact factor: 3.550

Review 5.  A review on synthetic chalcone derivatives as tubulin polymerisation inhibitors.

Authors:  Wenjing Liu; Min He; Yongjun Li; Zhiyun Peng; Guangcheng Wang
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.